Pfizer: FDA approves rare blood cancer treatment.
(CercleFinance.com) - The US Food and Drug Administration on Thursday approved a drug developed by Pfizer to treat a rare blood cancer that may be fatal within a matter of months.
The drug, Besponsa, chemically known as "inotuzumab ozogamicin", is designed to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The product was reviewed and approved under the FDA's breakthrough therapy designation and priority review programs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The drug, Besponsa, chemically known as "inotuzumab ozogamicin", is designed to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The product was reviewed and approved under the FDA's breakthrough therapy designation and priority review programs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.